[{"NetIncomeLoss_1_Q2_USD":-61651000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":17319000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":10110000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":16207880.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":16571322.0,"InterestIncomeOther_2_Q2_USD":251000.0,"InterestIncomeOther_1_Q2_USD":91000.0,"LiabilitiesNoncurrent_0_Q2_USD":594000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":55240000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":15000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-60789000.0,"AssetsCurrent_0_Q2_USD":326067000.0,"CommonStockSharesIssued_0_Q2_shares":16599522.0,"Assets_0_Q2_USD":327955000.0,"ShareBasedCompensation_2_Q2_USD":14275000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":997000.0,"PreferredStockSharesOutstanding_0_Q2_shares":1969797.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"Liabilities_0_Q2_USD":57304000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":594000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":-32000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":29000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":10018000.0,"CommonStockValue_0_Q2_USD":2000.0,"Revenues_2_Q2_USD":0.0,"Revenues_1_Q2_USD":0.0,"DepreciationDepletionAndAmortization_2_Q2_USD":202000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":97402000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":51632000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":130635000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1_Q2_USD":8179000.0,"StockIssuedDuringPeriodSharesNewIssues_2_Q2_shares":1087126.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-114229000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-61622000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":33540000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":810295000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":163328000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"IncreaseDecreaseInAccountsPayableTrade_2_Q2_USD":50000.0,"OtherIncome_1_Q2_USD":0.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":0.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-539661000.0,"CommonStockSharesOutstanding_0_Q2_shares":16599522.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":224071000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-90310000.0,"LiabilitiesCurrent_0_Q2_USD":56710000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":-20464000.0,"AccountsPayableCurrent_0_Q2_USD":1067000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":33540000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2221000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":8951000.0,"PreferredStockSharesIssued_0_Q2_shares":1969797.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":891000.0,"NetIncomeLoss_2_Q2_USD":-114197000.0,"OtherIncome_2_Q2_USD":273000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1208000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":46000.0,"ProfitLoss_2_Q2_USD":-114197000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"OperatingIncomeLoss_2_Q2_USD":-114721000.0,"OperatingIncomeLoss_1_Q2_USD":-61742000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":290306000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":327955000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":14275000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":8179000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":403000.0,"OperatingExpenses_2_Q2_USD":114721000.0,"OperatingExpenses_1_Q2_USD":61742000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":376000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-7.05,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-3.72,"StockholdersEquity_0_Q2_USD":270651000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":1630000.0,"Ticker":"MDGL","CIK":"1157601","name":"MADRIGAL PHARMACEUTICALS, INC.","OfficialName":"Madrigal Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1322434501.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]